{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:48:16Z","timestamp":1781664496867,"version":"3.54.5"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,26]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Despite optimal surgery and appropriate first-line chemotherapy, \u223c70\u201380\u2006% of patients with epithelial ovarian cancer will develop disease relapse. The prognosis is poor especially for women with Platinum resistant ovarian cancer. The standard treatment for these groups of patients is non-platinum-containing chemotherapy like taxanes, anthracyclines, gemcitabine, topotecan, and trabectedin. These drugs in various combinations and sequences provide modest survival or symptomatic benefit but with significant side effects. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a minimally-invasive drug-delivery technique specifically addressing limited tissue penetration and poor drug distribution with promising results. PIPAC is a novel method of delivering normothermic chemotherapy into the abdominal cavity as an aerosol under pressure. This concept seems to enhance the effectiveness of intra peritoneal chemotherapy by taking advantage of the physical properties of gas and pressure by generating an artificial pressure gradient and enhancing tissue uptake and distributing drugs homogeneously within the closed and expanded peritoneal cavity. Thus, due to the high local bioavailability during PIPAC, the chemotherapy dosage can be reduced which in turn largely prevents systemic side effects and organ toxicity.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n The study aims to investigate the therapeutic efficacy measured as objective tumour response according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria, of PIPAC in comparison with conventional Intravenous chemotherapy for women with recurrent platinum resistant ovarian cancer with peritoneal metastasis (PM). Consecutive patients diagnosed with PM secondary to platinum-resistant ovarian cancer will be randomized to PIPAC group or IV chemotherapy group. The primary objective of this study is to determine the efficacy after three cycles of PIPAC with cisplatin and doxorubicin in comparison with six cycles of systemic chemotherapy. The secondary outcome measures include morbidity and mortality, overall survival and disease specific survival. Analysis is by intention to treat.<\/jats:p>\n <\/jats:sec>\n \n Aim<\/jats:title>\n Assess the objective tumour response of PIPAC in comparison with systemic intravenous chemotherapy for women with platinum-resistant ovarian cancer.<\/jats:p>\n <\/jats:sec>\n \n Study type<\/jats:title>\n Prospective randomized control intervention trial.<\/jats:p>\n <\/jats:sec>\n \n Intervention model<\/jats:title>\n IV Chemotherapy group (Control group) PIPAC group (Experimental group)<\/jats:p>\n <\/jats:sec>\n \n Masking<\/jats:title>\n Open label.<\/jats:p>\n <\/jats:sec>\n \n Primary purpose<\/jats:title>\n Treatment.<\/jats:p>\n <\/jats:sec>\n \n Sample size<\/jats:title>\n Calculated sample size is 97 and rounded to 100. For each treatment group sample size of 50 will be considered.<\/jats:p>\n <\/jats:sec>\n \n Primary outcome criteria<\/jats:title>\n Objective tumour response according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1.<\/jats:p>\n \n Secondary outcome criteria<\/jats:title>\n \n \n Morbidity;<\/jats:p>\n <\/jats:list-item>\n \n Disease-specific survival (months between inclusion and death due to ovarian cancer);<\/jats:p>\n <\/jats:list-item>\n \n OS (months between inclusion and death due to any cause);<\/jats:p>\n <\/jats:list-item>\n \n CA 125 levels.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n PIPAC in women with platinum resistant ovarian PM has good response owing to superior tissue penetration and better drug distribution. The procedure is safe and well tolerated owing it to its minimal invasiveness. Typical side-effects of systemic chemotherapy, such as alopecia, peripheral neurotoxicity, nausea and myelosuppression are absent. We expect reduction of ascites with symptomatic relief and CA 125 levels. PIPAC is a novel technique for selected patients with platinum resistant ovarian PM and further investigation in comparative clinical trials with conventional chemotherapy will establish its role as a good palliative treatment option.<\/jats:p>\n <\/jats:sec>\n \n Ethics committee approval<\/jats:title>\n Obtained.<\/jats:p>\n <\/jats:sec>\n \n Status<\/jats:title>\n Recruiting.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n REF\/2018\/08\/021223 Registered on Clinical Trials Registry \u2013 India (CTRI);\n www.ctri.nic.in<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1515\/pp-2018-0111","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T04:07:43Z","timestamp":1551499663000},"source":"Crossref","is-referenced-by-count":16,"title":["Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer \u2013 study protocol for a randomized control trial"],"prefix":"10.1515","volume":"4","author":[{"given":"S. P.","family":"Somashekhar","sequence":"first","affiliation":[{"name":"Consultant Surgical & Gynec. Onco & Robotic Surgeon , HIPEC Super Specialist, Manipal Comprehensive Cancer Center, Manipal Hospital , Bangalore , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Ashwin","sequence":"additional","affiliation":[{"name":"Bangalore , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Rauthan","sequence":"additional","affiliation":[{"name":"Bangalore , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumar C.","family":"Rohit","sequence":"additional","affiliation":[{"name":"Bangalore , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"2025120909211361807_j_pp-2018-0111_ref_001_w2aab3b7b1b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5\u201329.10.3322\/caac.2125425559415","DOI":"10.3322\/caac.21254"},{"key":"2025120909211361807_j_pp-2018-0111_ref_002_w2aab3b7b1b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"Vasey PA, Herrstedt J, Jelic S. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol. 2005;16:i13\u201315.1588873610.1093\/annonc\/mdi823","DOI":"10.1093\/annonc\/mdi823"},{"key":"2025120909211361807_j_pp-2018-0111_ref_003_w2aab3b7b1b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology. 2005;68:293\u20138.1602095510.1159\/000086967","DOI":"10.1159\/000086967"},{"key":"2025120909211361807_j_pp-2018-0111_ref_004_w2aab3b7b1b1b6b1ab1b5b4Aa","doi-asserted-by":"crossref","unstructured":"Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615\u20139.10.1016\/j.ygyno.2011.02.01421414656","DOI":"10.1016\/j.ygyno.2011.02.014"},{"key":"2025120909211361807_j_pp-2018-0111_ref_005_w2aab3b7b1b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230\u201340.10.1056\/NEJMoa170861829342393","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909211361807_j_pp-2018-0111_ref_006_w2aab3b7b1b1b6b1ab1b5b6Aa","unstructured":"McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998;25:340\u20138.9633846"},{"key":"2025120909211361807_j_pp-2018-0111_ref_007_w2aab3b7b1b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Vermorken JC, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997;8:963\u20138.940216810.1023\/A:1008240421028","DOI":"10.1023\/A:1008240421028"},{"key":"2025120909211361807_j_pp-2018-0111_ref_008_w2aab3b7b1b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011;29:242\u20138.10.1200\/JCO.2009.27.8911","DOI":"10.1200\/JCO.2009.27.8911"},{"key":"2025120909211361807_j_pp-2018-0111_ref_009_w2aab3b7b1b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase III randomised trial. Lancet Oncol. 2013;14:236\u201343.2333311710.1016\/S1470-2045(12)70567-3","DOI":"10.1016\/S1470-2045(12)70567-3"},{"key":"2025120909211361807_j_pp-2018-0111_ref_010_w2aab3b7b1b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Canbay E, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15:623\u201336.10.1517\/14656566.2014.87957124617975","DOI":"10.1517\/14656566.2014.879571"},{"key":"2025120909211361807_j_pp-2018-0111_ref_011_w2aab3b7b1b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum resistant recurrent ovarian cancer: analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J Clin Oncol. 2015;33:3836\u20138.10.1200\/JCO.2015.63.140826282651","DOI":"10.1200\/JCO.2015.63.1408"},{"key":"2025120909211361807_j_pp-2018-0111_ref_012_w2aab3b7b1b1b6b1ab1b5c12Aa","unstructured":"Lihua P, Chen XY, Wu T. Topotecan for ovarian cancer. Cochrane Database Syst Rev. 2008;2:CD005589."},{"key":"2025120909211361807_j_pp-2018-0111_ref_013_w2aab3b7b1b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20:2311\u20136.10.1245\/s10434-012-2840-223377563","DOI":"10.1245\/s10434-012-2840-2"},{"key":"2025120909211361807_j_pp-2018-0111_ref_014_w2aab3b7b1b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Odendahl K, Solass W, Demtr\u00f6der C, Giger-Pabst U, Zieren J, Tempfer C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41:1379\u201385.10.1016\/j.ejso.2015.06.00126138283","DOI":"10.1016\/j.ejso.2015.06.001"},{"key":"2025120909211361807_j_pp-2018-0111_ref_015_w2aab3b7b1b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, et al. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132:307\u201311.2427515510.1016\/j.ygyno.2013.11.022","DOI":"10.1016\/j.ygyno.2013.11.022"},{"key":"2025120909211361807_j_pp-2018-0111_ref_016_w2aab3b7b1b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018;150:23\u201330. DOI:10.1016\/j.ygyno.2018.05.001.29743140","DOI":"10.1016\/j.ygyno.2018.05.001"},{"key":"2025120909211361807_j_pp-2018-0111_ref_017_w2aab3b7b1b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.10.1016\/j.ejca.2008.10.02619097774","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025120909211361807_j_pp-2018-0111_ref_018_w2aab3b7b1b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Sola\u00df W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surgical Oncol. 2013;20:3504\u201311.10.1245\/s10434-013-3039-x","DOI":"10.1245\/s10434-013-3039-x"},{"key":"2025120909211361807_j_pp-2018-0111_ref_019_w2aab3b7b1b1b6b1ab1b5c19Aa","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; published: May 28, 2009 (v4.03: June 14, 2010); U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda, MD, USA, 2010."},{"key":"2025120909211361807_j_pp-2018-0111_ref_020_w2aab3b7b1b1b6b1ab1b5c20Aa","doi-asserted-by":"crossref","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187\u201396.10.1097\/SLA.0b013e3181b13ca219638912","DOI":"10.1097\/SLA.0b013e3181b13ca2"},{"key":"2025120909211361807_j_pp-2018-0111_ref_021_w2aab3b7b1b1b6b1ab1b5c21Aa","unstructured":"Chow S, Shao J, Wang H. Sample size calculations in clinical research, 2nd ed. Chapman & Hall\/CRC Biostatistics Series, Boca Raton, Florida, USA, 2008:89."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/4\/1\/article-20180111.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0111\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0111\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:45:07Z","timestamp":1765277107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2018-0111\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3,26]]},"published-print":{"date-parts":[[2019,3,26]]}},"alternative-id":["10.1515\/pp-2018-0111"],"URL":"https:\/\/doi.org\/10.1515\/pp-2018-0111","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]},"article-number":"20180111"}}